Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
34.58 DKK | +1.11% | +3.16% | +5.56% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's high margin levels account for strong profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The company's attractive earnings multiples are brought to light by a P/E ratio at 11.39 for the current year.
- The company has a low valuation given the cash flows generated by its activity.
- The opinion of analysts covering the stock has improved over the past four months.
Weaknesses
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+5.56% | 4.81B | B- | ||
+20.70% | 72.16B | C+ | ||
-0.79% | 23.88B | C+ | ||
+8.25% | 8.35B | B | ||
+5.13% | 8.29B | C | ||
-19.42% | 8.18B | B- | ||
+16.83% | 4.4B | B+ | ||
-1.83% | 4B | B- | ||
-1.65% | 3.92B | B | ||
+26.97% | 3.79B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- HLUN B Stock
- Ratings H. Lundbeck A/S